Back to top


  /    /  LACOG 0221 – BRAVE

Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (LACOG 0221) – BRAVE Study

Type of Study: Epidemiological

Sponsor / Support: LACOG, GBECAM

Primary Objectives: Describe the first-line treatment of hormone receptor-positive, HER2- negative metastatic breast cancer in Brazil.

Design: This is an observational, retrospective cohort study.

Sample Size: 300 patients

Principal Investigator: Gustavo Werutsky

Countries LATAM: Brazil Identifier: NCT05034393